Dupilumab Injection in the Management of Steroid-Induced Rosacea: A New Case Report  

作　　者：Waqas S. Abdulwahhab Alaa S. Mehair Waqas S. Abdulwahhab;Alaa S. Mehair(Consultant Dermatology & Venereology/Department of Dermatology and Venereology, Al Qassimi Hospital, Sharjah, United Arab Emirates;Department of Dermatology and Venereology, Al Qassimi Hospital, Sharjah, United Arab Emirates)

机构地区：[1]Consultant Dermatology & Venereology/Department of Dermatology and Venereology, Al Qassimi Hospital, Sharjah, United Arab Emirates [2]Department of Dermatology and Venereology, Al Qassimi Hospital, Sharjah, United Arab Emirates

出　　处：《Journal of Cosmetics, Dermatological Sciences and Applications》2021年第1期10-17,共8页化妆品、皮肤病及应用期刊（英文）

摘　　要：<strong>Background:</strong> Topical corticosteroids (TCS) are used frequently for various inflammatory skin conditions. The prolonged daily and inappropriate use of TCS may cause adverse effects such as erythema, atrophy, and telangiectasia. Steroid rosacea or addiction is a distinct adverse effect of inappropriate use of TCS. It occurs most commonly in adult women applying mid- or high-potency TCS to the face. Dupilumab is an interleukin 4 (IL-4) receptor α-antagonist approved for treatment Moderate-to-Severe Atopic Dermatitis in childhoods and adults. The role of dupilumab injection in steroid-induced rosacea management is rarely discussed. <strong>Aim:</strong> To document a new case presentation of atopic dermatitis on high potency topical facial steroid addiction for a duration of 4 years in a young female patient who was successful treated with dupilumab injection and withdrawal therapy. <strong>Case Report:</strong> A 32-year-old female patient with a history of atopic dermatitis presented with a history of worsening pruritic facial rashes for a one-month duration and on high potency TCS (Clobetasol Propionate ointment 0.05%) since 4 years ago with multiple treatments failure of steroidal withdrawal treated successfully in combination with dupilumab injection. <strong>Conclusion:</strong> Dupilumab injection considers effective and inducing rapid resolution of signs and symptoms of steroid-induced rosacea in patients with a history of atopic dermatitis in combination with withdrawal therapy without a rebound effect.<strong>Background:</strong> Topical corticosteroids (TCS) are used frequently for various inflammatory skin conditions. The prolonged daily and inappropriate use of TCS may cause adverse effects such as erythema, atrophy, and telangiectasia. Steroid rosacea or addiction is a distinct adverse effect of inappropriate use of TCS. It occurs most commonly in adult women applying mid- or high-potency TCS to the face. Dupilumab is an interleukin 4 (IL-4) receptor α-antagonist approved for treatment Moderate-to-Severe Atopic Dermatitis in childhoods and adults. The role of dupilumab injection in steroid-induced rosacea management is rarely discussed. <strong>Aim:</strong> To document a new case presentation of atopic dermatitis on high potency topical facial steroid addiction for a duration of 4 years in a young female patient who was successful treated with dupilumab injection and withdrawal therapy. <strong>Case Report:</strong> A 32-year-old female patient with a history of atopic dermatitis presented with a history of worsening pruritic facial rashes for a one-month duration and on high potency TCS (Clobetasol Propionate ointment 0.05%) since 4 years ago with multiple treatments failure of steroidal withdrawal treated successfully in combination with dupilumab injection. <strong>Conclusion:</strong> Dupilumab injection considers effective and inducing rapid resolution of signs and symptoms of steroid-induced rosacea in patients with a history of atopic dermatitis in combination with withdrawal therapy without a rebound effect.

关 键 词：CORTICOSTEROID Steroid Rosacea Atopic Dermatitis Dupilumab 

分 类 号：R73[医药卫生—肿瘤]